TrialCancer2017

Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).

Aarti K Bhatia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.